Here is an animation of Boston Scientific’s Vessix renal denervation system. Boston Scientific CEO Mike Mahoney was quoted by Qmed as being “optimistic” about renal denervation and the Vessix system despite Medtronic’s Symplicity system having failed on efficacy in a pivotal US clinical trial.
Mahoney was quoted in Qmed as pointing to the ease of use and speed of the Vessix system. He told Qmed: “We think it is a better platform. Mahoney also outlined that Boston Scientific would take time to evaluate the clinical results of the Symplicity-3 trial and use the information to determine the course of the company’s clinical strategy.
